Analysis of risk factors related to thyroid function abnormality caused by programmed death-1 inhibitors
10.12025/j.issn.1008-6358.2025.20250550
- VernacularTitle:程序性死亡受体1抑制剂导致甲状腺功能异常相关因素分析
- Author:
Lihong WANG
1
;
Huiyang SONG
2
;
Shufei ZANG
2
;
Ling YE
3
;
Xuefei DANG
4
Author Information
1. Department of Endocrinology, Shanghai Tenth People’s Hospital, School of Medicine, Tongji University, Shanghai 200072, China.
2. Department of Endocrinology, Shanghai Fifth People’s Hospital, Shanghai 200240, China.
3. Department of Pharmacy, Minhang District Cancer Hospital, Shanghai, Shanghai 200240, China.
4. Department of Oncology, Minhang District Cancer Hospital, Shanghai, Shanghai 200240, China.
- Publication Type:Monographicreport:Diagnosisandtreatmentoftumorimmunotherapy-relatedendocrinecomplications
- Keywords:
programmed death-1 inhibitor;
malignant tumor;
thyroid function abnormality;
immune-related adverse event
- From:
Chinese Journal of Clinical Medicine
2025;32(4):544-550
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical characteristics and influencing factors of thyroid function abnormality (TFA) in patients with malignant tumors receiving programmed death-1 (PD-1) inhibitor therapy, and its correlation with PD-1 inhibitors. Methods A retrospective analysis was conducted on the clinical data and biochemical indicators of 669 patients with malignant tumors who received PD-1 inhibitor therapy. Of these, 561 patients maintained normal thyroid function (normal group), while 108 developed TFA (TFA group). Baseline characteristics, PD-1 inhibitor type, tumor type, and other indice were compared between the two groups. Univariate and multivariate logistic regression analyses were performed to identify related factors for TFA development. Additionally, the relationship between PD-1 inhibitors and TFA types was further analyzed within the TFA group. Results The rates of patients treated with pembrolizumab and with respiratory tumors were significantly higher in TFA group than those in the normal group (P＜0.01). Multivariate logistic regression analysis revealed that treatment with pembrolizumab and with respiratory tumor increased 5.350 and 1.514 times than tislelizumab and digestive tumor for risk of TFA development, respectively (P＜0.01). Within the TFA group, hypothyroidism was the predominant type (75, 69.4%); treatment with pembrolizumab increased 2.999 times than tislelizumab for development risk of hyperthyroidism (P＝0.042). Conclusions Among patients with malignant tumors treated with PD-1 inhibitors, pembrolizumab is more frequently associated with TFA, and patients with respiratory tumors were at a higher risk of developing TFA. Clinicians should closely monitor thyroid function in patients with respiratory tumors treated with pembrolizumab.
